UBS Knock-Out BAYN/ DE000UH08S90 /
6/11/2024 4:31:55 PM | Chg.-0.040 | Bid5:10:56 PM | Ask5:10:56 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.350EUR | -10.26% | 0.350 Bid Size: 150,000 |
0.360 Ask Size: 150,000 |
BAYER AG NA O.N. | 23.606 EUR | 12/31/2078 | Call |
GlobeNewswire
1:05 PM
Banks are making climate commitments, but are they actually making a difference?
GlobeNewswire
1:00 PM
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
5/30
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire
5/30
BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire
5/2
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire
4/18
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire
4/16
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire
4/11
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire
3/25
BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire
3/6
BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
GlobeNewswire
3/4
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
GlobeNewswire
2/13
Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire
2/13
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure